Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here I find my answer for myself: http://www.euthymics.com/DOV-FAQs.html
Q: Did the former DOV Board of Directors get any other benefits from the merger, financial or otherwise, than I got?
A: Like all DOV stockholders, former members of the DOV Board of Directors are entitled to receive approximately $.013 per share (or $12.90 (approximately) in cash for each 1,000 shares of stock they owned), plus an additional $.002 (approximately) per share (or $2.68 per 1,000 shares) if certain escrow release conditions are met. Two former officers of DOV also received compensation pursuant to their severance contracts with DOV which provided for additional payments in the event of a successful sale of DOV.
So as a DOV shareholders I can't partecipate in the new company
But I will receive a cash payment from escrow agent.....
I would like to partecipate as a shareholder in the newco but it's a private things.... good company are only privately held......
Bye
" .... The merged company will operate as a privately held corporation with headquarters in Cambridge, Massachusetts. ..... "
What does this mean?
that the new company will no longer be listed ?????
What will happen to the stocks that I own now?
Euthymics Bioscience, Inc. Closes $24 Million Series A Financing and Completes Acquisition of DOV Pharmaceutical
--Company Will Develop a Novel Triple Reuptake Inhibitor Antidepressant for the Largest Single Segment of Patients with Major Depression--
CAMBRIDGE, Mass., Jul 22, 2010 (BUSINESS WIRE) -- --Euthymics' Approach Designed to Improve Efficacy and Address the Leading Causes of Drug Discontinuation--
Euthymics Bioscience, Inc., a clinical-stage company developing next-generation antidepressants, today announced the completion of a Series A financing -- led by Novartis Venture Funds and Venture Investors -- for a total investment commitment of $24 million in milestone-conditioned tranches. Hambrecht & Quist Capital Management, LLC, GBS Venture Partners and the State of Wisconsin Investment Board also participated in the financing. The initial Series A proceeds were used to complete the acquisition of DOV Pharmaceutical, Inc. and allow for the continued development of DOV's unique antidepressant, EB-1010 (formerly known as DOV 21,947), for patients who do not respond adequately to selective serotonin reuptake inhibitors, or SSRIs. The merged company will operate as a privately held corporation with headquarters in Cambridge, Massachusetts.
"This impressive commitment speaks to the potential of our clinical-stage entry into the antidepressant market," said Anthony A. McKinney, President, CEO and co-founder of Euthymics. "We are addressing a significant unmet medical need, we have convincing Phase II proof-of-concept efficacy in major depression and we anticipate the start of a Phase II/III trial in the first half of 2011."
Euthymics' lead product, EB-1010, is intended for the estimated two-thirds of major depression patients who do not respond adequately to SSRIs. This segment is the single largest group of patients with depression and represents a major unmet medical need. EB-1010 is a novel unbalanced triple reuptake inhibitor which modulates serotonin, norepinephrine and dopamine. By "tuning" the affinity for each of these neurotransmitters in one molecule, EB-1010 is designed to improve efficacy and reduce side effects of current antidepressants, including weight gain, sexual dysfunction and cognitive impairment without the need for multiple prescriptions or complex titrations. The EB-1010 ratio of serotonin, norepinephrine and dopamine modulation is very similar to the triple combination given as multiple medications that was shown to improve outcomes in STAR*D, the large federally funded trial in major depression. EB-1010 has demonstrated proof-of-concept efficacy and attractive tolerability in patients with major depression.
"The antidepressant prescription market is among the largest, with an excess of 200 million prescriptions dispensed annually in the U.S. and a value exceeding $20 billion worldwide," said Campbell Murray, M.D., Managing Director of Novartis Venture Funds, who will serve as Euthymics' Chairman. "Euthymics enters this field with a ready-made market of underserved patients, a clinical-stage drug and an executive team with an impressive track record. In short, we have all the ingredients for success for our company and for our patients."
Euthymics is led by an experienced management team. President and CEO Anthony McKinney was one of the original executives at Orexigen, where, as Chief Operating Officer, he helped take the company public and move its lead products into the clinic. He was also a member of the founding management team at Novazyme, and was Senior Vice President and General Manager at Genzyme after it acquired Novazyme for $137 million. Euthymics was co-founded by Franklin P. Bymaster, who will serve as Chief Scientific Officer. Bymaster spent over 33 years at Lilly and was involved with many of its successful CNS drugs including Prozac, Zyprexa, Strattera and Cymbalta.
Joining the Euthymics Board along with Dr. Murray are Paul Weiss, Ph.D., of Venture Investors, Frank Gentile, Ph.D., of Hambrecht & Quist Capital Management, LLC and Andrew Baker, Ph.D., of GBS Venture Partners.
When clinical trials begin next year, Maurizio Fava, M.D., Professor of Psychiatry at Harvard Medical School, Executive Vice Chair of the Department of Psychiatry at Massachusetts General Hospital and one of the leading depression experts worldwide, will serve as principal investigator.
In addition to EB-1010 for depression, the DOV acquisition gives Euthymics a pipeline of monoamine reuptake inhibitors for other CNS disorders including ADHD, obesity, anxiety, obsessive compulsive disorder and drug addiction.
About Euthymics Bioscience, Inc.
Euthymics Bioscience, Inc. is a neuroscience-focused clinical-stage company developing next-generation treatments for depression. Euthymics' initial focus is on patients who do not respond adequately to SSRIs. EB-1010 for depression is expected to improve efficacy and reduce the leading side effects associated with poor adherence to standard antidepressants including weight gain, sexual dysfunction and cognitive impairment. Euthymics is a private Delaware corporation with headquarters in Cambridge, Massachusetts. Additional information can be found on the company's website at www.euthymics.com.
SOURCE: Euthymics Bioscience, Inc.
CONTACT:
Media: BioCom Partners Stephen Gendel, Jennifer Anderson, 212-918-4650 or Investors: Euthymics Bioscience, Inc. Anthony A. McKinney, 617-674-3830
Copyright Business Wire 2010
**********************************************************************
As of Sunday, 07-18-2010 23:59, the latest Comtex SmarTrend? Alert, an automated pattern recognition system, indicated an UPTREND on 06-10-2010 for NVS @ $47.16.
For more information on SmarTrend, contact your market data provider or go to www.mysmartrend.com
SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright ? 2004-2010 Comtex News Network, Inc. All rights reserved.
-0-
KEYWORD: United States
North America
Massachusetts
INDUSTRY KEYWORD: Health
Biotechnology
Mental Health
Pharmaceutical
Professional Services
Finance
SUBJECT CODE: Funding
Product/Service
Merger getting voted by shareholders:
PROPOSAL TO APPROVE AND ADOPT THE AGREEMENT AND PLAN OF MERGER DATED AS OF JUNE 28, 2010, BY AND BETWEEN DOV PHARMACEUTICAL, INC. AND EUTHYMICS BIOSCIENCE, INC., A DELAWARE CORPORATION, PURSUANT TO WHICH EUTHYMICS BIOSCIENCE, INC. WILL BE MERGED WITH AND INTO DOV PHARMACEUTICAL, INC.
Prior history of Euthymics CEO (if this is the same guy)
Member of the founding management team of Novazyme Pharmaceuticals
Senior vice president and GM at Genzyme( NASDAQ 56.95) Corp that bought out Novazyme
Cheif operating officer of Orexigen Theraputics (NASDAQ 6.95)
mlkr-.015 isnt a whole lot. I dont own any but been watching this for years to see the out come.
BEING BOUGHT only stingy 2 m. MFs.
Euthymics Bioscience, Inc. Announces Letter of Intent for Acquisition of DOV Pharmaceutical, Inc.
Date : 02/12/2010 @ 7:15AM
Source : PR Newswire
Stock : (DOVP)
Quote : 0.015 0.0 (0.00%) @ 7:57AM
Euthymics Bioscience, Inc. Announces Letter of Intent for Acquisition of DOV Pharmaceutical, Inc.
SAN DIEGO, Feb. 12 /PRNewswire/ --
Euthymics Bioscience, Inc., a privately held Delaware corporation, today announced that it has signed a non-binding Letter of Intent (LOI) to merge into and acquire DOV Pharmaceutical, Inc. (DOV), a Delaware corporation currently traded on the Pink Sheets (Pink Sheets: DOVP), for $2.0 million in cash plus payment of certain of DOV's expenses. DOV believes that the contemplated $2.0 million cash payment to shareholders represents approximately $0.015 per share of DOV common stock. If the transaction is consummated, it is anticipated that DOV will be renamed Euthymics Bioscience, Inc.
Completion of the acquisition is subject to the satisfaction of several conditions, including, without limitation, the execution of a definitive merger agreement, the satisfactory completion of due diligence, the completion of financial statements
by Euthymics, compliance with applicable laws, approval by DOV shareholders, and other conditions. The LOI provides for an exclusivity period and also for a break-up fee in the event that DOV accepts an alternative offer from a third party.
About DOV Pharmaceutical, Inc.
DOV is a biopharmaceutical company historically focused on the development of novel product candidates for disorders of the central nervous system. DOV has previously funded drug development and discovery programs that are now at the preclinical, Phase I and Phase II clinical stages focused on monoamine reuptake inhibitors.
About Euthymics Bioscience, Inc.
Euthymics Bioscience, Inc. is a neuroscience-focused clinical-stage company developing next generation treatments for depression, ADHD and other CNS disorders.
Safe Harbor Statements under the Private Securities Litigation Reform Act of 1995:
Contacts: Euthymics Bioscience, Inc.
Anthony A. McKinney Presi
Dave waz going on? Lower range now: 0.012-0.012 100ks volume!
Have a bunch.. waiting. Shot an email to the contact people at DOVP and asked what was going on with the sale of the assets. Of course they couldn't comment, but Barbara Duncan cited the latest 8K which stated that "The Company operates on a very limited basis and is focused on soliciting interest in the sale or license of the Company's business and assets, either as a single entity or in a series of transactions." Something will happen soon either way - imho.
day's range:0.016-0.025.. volume is getting thin..dave waz going on/ did u quit accumulating?
GL
i got so may.. but put a buy order again @0.015 just in case.. not to mention many worthless warrants as well..
DOVP -.027 up 26% - Still believe this has one final run in it. They may try to move it and blow off the remaining paper, something may be happening with the company assets, or their is a suitor for the shell. Somebody, besides me has been slowly accumulating shares from .01.
the dave; rare believer.
Could run to .10 easily. Stock is very thin and has been under accumulation. Something's percolating. They may have finally found a suitor for the company or a buyout of their patents. Breakout above 200dma at .025 is key. Watch volume.
something unusual. 1.57 m volume.. 354 percent up at one point. sure not IH "manipulators". no news!
bought some at .02 on the chart break and it still seems strong, anyone know anything? cant find any news
tia
During this time Barbara Duncan, the Chief Executive Officer of the Company, and Dr. Phil Skolnick, its President and Chief Scientific Officer, will continue to solicit interest in the sale or license of the Company's business and assets, either as a single entity or in a series of transactions.
THIS CO HAS VALUE!!!!!!!!
ITEM. 8.01. OTHER EVENTS.
DOV reported today that its Board of Directors met on November 25, 2008 for a regularly scheduled meeting to consider and discuss a number of pending matters. All of the members of the board attended the meeting, either in person or via teleconference, except for Mr. Joseph Zakzrewski, who had previously submitted his resignation effective November 23, 2008.
Foremost among the matters discussed was the Company's rapidly deteriorating financial condition. Based on the recently reported results from the bicifadine Phase 2b clinical trial for the treatment of diabetic neuropathic pain, the Company will not receive any milestone payment this year from its sublicensee, nor does the Company anticipate a milestone payment for bicifadine in the future.
In the absence of the milestone payment, the Company's alternatives for raising cash are few, and would be limited to either the sale of the Company or monetizing the remaining assets of the Company, either through a sale or license, if possible. After reviewing the Company's cash resources, the board approved further expense reductions, including the immediate termination of the remaining clinical trial being conducted by the Company, the phase II study of DOV 21,947 in patients with major depressive disorder. In addition, the board approved the termination of the majority of the Company's remaining employees. Operations will continue, but these reductions in force could have an adverse affect on the Company's financial internal controls and procedures. The Company expects its current financial resources will permit it to continue operating through perhaps the first quarter of calendar 2009. During this time Barbara Duncan, the Chief Executive Officer of the Company, and Dr. Phil Skolnick, its President and Chief Scientific Officer, will continue to solicit interest in the sale or license of the Company's business and assets, either as a single entity or in a series of transactions.
--------------------------------------------------------------------------------
Add DOVP.OB to Portfolio Set Alert Email to a Friend
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for DOVP.OB - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial????? Sign Up Now
--------------------------------------------------------------------------------
Copyright © 2008 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein
What a buying opp,,8k filed nice volume,,,i believe the co
is up for sale
what a drop
TOP TEN ON THE YAHOO BOARD
http://messages.yahoo.com/sitemap
dead here... i guess all momentum players are gone..or show no interest...
new support levels setting!
As virgo foresees, december 2007 will be a crucial month.. Asset revaluation: $1.00 PPS would be a minimum expectation..
GLLs
good news with bond issue..may be leading to a higher asset value? higher asks getting thicker..right after 5 millions shares trade day?
INSIDERS' BUYING/OWNERSHIP..
CURRENT SITUATION
UBS AG 12,249,875,500 SHARES
HIGHBRIDGE CAPITAL +13 M SHARES
POLYGON INVESTMENT LLC +12 M SHARES
BARBARA DUNC +5 M SHARES
SKOLNICK +5 M SHARES
IT SEEMS AFTER SLEEZY OFFICERS SOLD DOVP @ PEAK THEY STARTED TO ACCUMULATE AGAIN..
I BET THEY ARE FREE RIDERS..
ANY TIP AS TO THE COST OF OFFICERS' SHARES?
TIA
GLLs
Volume movement few days...Slightly below 100k today which is light..I guess we have to wait news to move it higher..
DOVP is getting bussy along with NBIX since FDA accepted resubmission of indiplon; Dec '07 will be crucial for approval process. I increased my stake...still in red .. Took some off the table . Will buy more ..
That was a high flyer in the 1980's with the girls. I looked at the PR and to tekk ya the honest truth I have no clue if this product will make a come back.
I sold too, put $$ into dans...check it out any news from danskin pps goes to $2+ have to pay ask to get any though soooo hard to get.:)
Ok I am OUT on this news on a break even basis I am happy to say.
Good luck to everyone still holding!
DOV Pharmaceutical, Inc. Announces Successful Closing of Exchange Offer for 2.50%... [GVLFPLS]
DOV Pharmaceutical, Inc. Announces Successful Closing of Exchange Offer for 2.50% Convertible Subordinated Debentures Due 2025
SOMERSET, N.J., March 15 /PRNewswire-FirstCall/ -- DOV Pharmaceutical, Inc. ("DOV" or the "Company") (Pink Sheets: DOVP.PK) announced today that it has accepted all of its 2.50% Convertible Subordinated Debentures due 2025 (the "Debentures") that were tendered in its exchange offer (the "Exchange Offer") which expired yesterday at 5:00 p.m., New York City time. The Exchange Offer, as amended, was conditioned upon the valid tender of at least 96.3% of the aggregate principal amount of outstanding Debentures. Through the expiration of the Exchange Offer, DOV received tenders of and accepted for exchange Debentures in the aggregate principal amount of $67,473,000, representing approximately 96.4% of the $70.0 million in aggregate principal amount of outstanding Debentures.
As a result of the closing of the Exchange Offer and in exchange for the tendered Debentures, DOV will deliver today to Wells Fargo Bank, N.A., the exchange agent for the Exchange Offer, an aggregate cash payment of $14.3 million and will issue and deliver today an aggregate of 439,784 shares of Series C Convertible Preferred Stock and an aggregate of 100,000 shares of Series D Convertible Preferred Stock to the holders who tendered their Debentures in the Exchange Offer. The Series C and D Convertible Preferred Stock will be convertible by the holders into shares of common stock following stockholder approval and filing of an amendment to DOV's charter increasing the number of shares of authorized common stock as necessary to accommodate such conversion and the Series C Convertible Preferred Stock also will automatically convert 30 days following the filing of the amendment to DOV's charter or earlier in certain circumstances. Generally, the Series C Convertible Preferred Stock votes with the common stock as a single class on an as-converted basis, and entitles the holders of a majority of the Series C Convertible Preferred Stock to initially appoint a majority of DOV's Board of Directors. The Series D Convertible Preferred Stock has no voting rights except as required by law, does not have any initial stated liquidation preference, does not mandatorily convert into common stock and restricts a holder's ability to convert if such holder would beneficially own in excess of 9.9% of the Company's capital stock entitled to vote generally.
The Debentures that were not tendered in this Exchange Offer will remain outstanding pursuant to the original terms of the Indenture governing the Debentures with a contractual interest rate of 2.5% per annum and a maturity of 2025.
Additionally, DOV will issue to holders of its common stock 30,000,000 warrants to purchase additional shares of common stock with an exercise price of approximately $0.523 per share. Such warrants will be exercisable on and after July 1, 2007 until December 31, 2009 and will be issued to holders as of a record date to be set by DOV's Board of Directors.
"We thank our investors and employees for their support and patience throughout this restructuring. As a result of the successful closing of the Exchange Offer, we will continue our focus on the development of products emanating from our core areas of research and early stage clinical programs and work to build shareholder value," said Barbara Duncan, Chief Executive Officer of DOV.
This press release may be deemed to be solicitation material in respect of the potential proposal to stockholders to increase the number of authorized shares of common stock of DOV. In connection with such proposal, DOV has filed with the SEC a preliminary proxy statement and expects to file a definitive proxy statement and other relevant materials in the near future. Stockholders are urged to read the proxy statement and any other relevant materials filed by DOV because they will contain important information. Once the materials are filed with the SEC, they are available free of charge at the SEC's website -- www.sec.gov. In addition, DOV will provide copies of these documents free of charge to stockholders upon request to Investor Relations (732.907.3600).
DOV and its executive officers and directors may be deemed to be participants in the solicitation of proxies from DOV stockholders in favor of any such proposal. Stockholders may obtain information regarding the direct and indirect interests of DOV and its executive officers and directors with respect to the proposal by reading the proxy statement, if and when filed with the SEC.
About DOV
DOV is a biopharmaceutical company focused on the discovery, acquisition and development of novel drug candidates for central nervous system disorders. The Company's product candidates address some of the largest pharmaceutical markets in the world including depression, pain and insomnia. SOURCE DOV Pharmaceutical, Inc.
Investor Relations and Corporate Communications for DOV Pharmaceutical, Inc., +1-732-907-3600 15Mar07 11:07 GMT
Symbols: us;DOVP
Source PRN PR Newswire
Categories: NWI/BIO NWI/FIN NWI/HEA NWI/MTC NWI/OTC NWS/TNM MST/I/BNK MST/I/BTC MST/I/DRG MST/I/HEA MST/I/MKT MST/L/EN MST/R/US/NJ MST/S/MRG TGT/PRX
Neurocrine to submit NDA for Indiplon AGAIN in 2Q07
The market woke to investor pleasing news from Neurocrine biosciences, Inc. which plans to resubmit the new drug application for the immediate release (IR) insomnia drug indiplon during the second quarter, with review likely taking about 6 months.
After trading ended monday, Neurocrine disclosed that another safety and efficacy trial will not be done for the compound, a non-benzodiazepine agent that acts on a specific site of the GABA-A receptor that is designed for use as needed by patients, whether to fall asleep quickly or go back to sleep after waking in the night.
After talks with the agency [FDA] the odds of indiplon's approval "are so high that to spend $20 million on an 'insurance' study they didnt ask for would not be prudent." Instead, neurocrine will spend the money on pre-commercial work and phase IIIb/IV activities.
The companies shares NBIX closed tuesday at $13.88, up 93 cents. TODAY- NBIX closed at $14.02.